2Green J R,Guenther A.The backbone of progress-preclinical studies and innovations with zoledronic acid[J].Crit Rev Oncol Hematol,2011,77(Suppl 1):S3-S12.
3Mundy G R,Yoneda T,Hiraga T.Preclinical studies with zo-ledronic acid and other bisphosphonates:impact on the bone microenvironment[J].Semin Oncol,2001,28(2 Suppl 6):35-44.
4Helm N B,Padala S,Beck F M,et al.Short-term zoledronic ac-id reduces trabecular bone remodeling in dogs[J].Eur J Oral Sci,2010,118(5):460-465.
6Evans C E,Braidman I P.Effects of two nevel bisphosphonates on bone cells in vitro[J].Bone Miner,1994,26(2):95-107.
7Willey J S,Livingston E W,Robbins M E,et al.Risedronate pr-events early radiation-induced osteoporosis in mice at multiple skeletal locations[J].Bone,2010,46(1):101-111.
8Skerjanec A,Berenson J,Hsu C,et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
9Neville-Webbe H,Coleman R E.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med,2003,17(6):539-553.
10Pampu A A,Dolanmaz D,Tüz H H,et al.Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits[J].J Oral Maxillofac Surg,2008,66(5):905-910.
3Kyle R A, Rajkumar S V. Multiple Myeloma [J]. N Engl J Med, 2004,351(18) : 1860-1873.
4Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines [J]. Leukemia, 2000,14 (5) : 841.
5Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronie acid [J]. J Pharmacol Exp Ther, 2002,302 ( 3 ) : 1055.
6Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadeha T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma [J]. Blood, 2000, 96(2) :384.
7Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of pro MMP-2, and induction of MMP-1 by myeloma cells [J]. Blood, 1997,90(4) : 1649.
8Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials [J]. J Clin Oncol, 2001,19(2):558.
9Rosen L S, Gordon D, Kaminski M, et al, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase Ⅲ, double-bllnd, eomparativetrial [J]. Cancer J, 2001,7 (5) : 377.
10Rosen L S, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial [J]. Cancer, 2003,98 (8) :1735.
